Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Mz4.5
Meso-Zeaxanthin – Forschung
Hilft wahrscheinlich
41 begutachtete Studien
Was die Evidenz sagt
Hilft wahrscheinlich
Meso-Zeaxanthin scheint in 3 von 3 Studien mit messbaren Effekten zu helfen — die Evidenz tendiert klar ins Positive.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 2011–2026 mit einer typischen Studiengröße von 67 Teilnehmenden.
Basierend auf 41 Studien · 3 Meta-Analysen · 25 RCTs · 7,837 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Was die Studien gefunden haben
3geholfen· 38 weitere ohne bewertete Effektdaten
Nach Outcome
Vision & macular pigmentErhöht das Makulapigment und kann Blendempfindlichkeit/Kontrast verbessern (Surrogatmaße); kein nachgewiesener Nutzen bei der AMD-Progression · 3-6 Monate
Hilft wahrscheinlich38 Studien
Cognitive function
Überwiegend Mechanismus / Beobachtung25 Studien
Neuroprotection & brain aging
Überwiegend Mechanismus / Beobachtung7 Studien
Therapeutic & clinical
Überwiegend Mechanismus / Beobachtung6 Studien
Inflammation
Überwiegend Mechanismus / Beobachtung3 Studien
Safety profile
Überwiegend Mechanismus / Beobachtung3 Studien
Heart & blood pressure
Zu wenige bewertete Studien1 Studie
Anxiety & stress
Zu wenige bewertete Studien1 Studie
Women's health
Zu wenige bewertete Studien1 Studie
In Zahlen
Aus 22 Studien mit messbaren Effekten gezogen
Wahrscheinlich echte Effekte
75%
über Studien hinweg
Untersuchte Personen
7,837
typische Studie: 67 Personen
Stärkste Designs
28
3 gepoolt, 25 randomisiert
Zeigte Nutzen
100%
3/3 Studien
Wie lange Studien liefen
1–3 Monate
2
3+ Monate
4
Untersuchte Populationen
General population3
Subjects with and without age-related macular degeneration2
Adults with healthy eyes (mean age 43 years)1
Glaucomatous patients1
Aktives Forschungsgebiet
18 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2024
201120182026
1Meta-AnalyseCited 8×n=3,159 · very large study2024
All groups significantly increased macular pigment optical density and contrast sensitivity at low spatial frequency, whereas only the antioxidant mixture + lutein (L) + fatty acid combination exhibited significant improvements in visual acuity.
2Macular pigment optical densityMeta-AnalyseCited 54×n=3,189 · very large study2021
Our objective was to determine a minimum concentration of lutein/zeaxanthin intake that is associated with a statistically significant and/or clinically important change in macular pigment optical ...
Wilson LM et al. · Advances in nutrition (Bethesda, Md.) (2021)
Spürbar Nutzen
← SchlechterKein EffektBesser →
Our objective was to determine a minimum concentration of lutein/zeaxanthin intake that is associated with a statistically significant and/or clinically important change in macular pigment optical density (MPOD) among adults with healthy eyes.
We included 46 studies (N = 3189 participants; mean age = 43 y; 42% male).
There was no statistically significant change in MPOD among studies evaluating <5 mg/d of total lutein/zeaxanthin intake which primarily assessed dietary interventions for 3-6 mo (pooled mean difference, 0.02; 95% CI: -0.01 to 0.05).
Retinal carotenoids attenuate A2E formation and can directly and indirectly alleviate A2E-mediated oxidative damage.
Arunkumar R et al. · Advances in experimental medicine and biology (2023)
The pyridinium bisretinoid, N-retinylidene-N-retinylethanolamine (A2E), contributes to drusen formation in dry age-related macular degeneration (AMD) and to the autofluorescent flecks in autosomal recessive Stargardt disease (STGD1).
Retinal carotenoids attenuate A2E formation and can directly and indirectly alleviate A2E-mediated oxidative damage.
In this chapter, we review these more recently recognized interconnections between MP carotenoids and A2E bisretinoids.
The data suggest that carotenoid vitamin therapy exerts synergic neuroprotective benefits and has the capacity to serve adjunctive therapy in the management of glaucoma.
Lem DW et al. · Nutrients (2021)
A comprehensive literature search was conducted in three databases (PubMed, Cochrane Library, and Web of Science) and 20 records were identified for screening.
Lutein demonstrated enhanced neuroprotection on retinal ganglion cell survival and preserved synaptic activity.
In clinical studies, a protective trend was seen with greater dietary consumption of carotenoids and risk of glaucoma, while greater carotenoid levels in macular pigment were largely associated with improved visual performance in glaucomatous eyes.
These findings provide a strong molecular basis and a line of evidence that suggests carotenoid vitamin therapy may offer enhanced neuroprotective effects with therapeutic potential to function as an adjunct nutraceutical strategy for management of diabetic retinopathy.
Lem DW et al. · Nutrients (2021)
Lutein and zeaxanthin demonstrated significant protection against capillary cell degeneration and hyperglycemia-induced changes in retinal vasculature.
Observational studies indicate that depletion of xanthophyll carotenoids in the macula may represent a novel feature of DR, specifically in patients with type 2 or poorly managed type 1 diabetes.
Meanwhile, early interventional trials with dietary carotenoid supplementation show promise in improving their levels in serum and macular pigments concomitant with benefits in visual performance.
A laboratory methods chapter on extracting, detecting, and imaging the macular carotenoids; its background notes the observational association between higher macular carotenoids and lower AMD risk.
Li B et al. · Methods in enzymology (2022)
Background context notes that higher intraretinal carotenoid levels are observationally associated with lower AMD risk (not an interventional finding from this chapter).
Reviews carotenoid extraction methods from retina, RPE/choroid, serum and liver across human and animal models.
Reviews macular-carotenoid detection by spectroscopy and HPLC (cyano, chiral, and C30 columns).
Dietary lutein and zeaxanthin intake increased MPOD in six of the seven clinical trials and significantly improved most of the cognitive functions studied.
García-Romera MC et al. · Physiology & behavior (2022)
Dietary lutein and zeaxanthin intake increased MPOD in six of the seven clinical trials and significantly improved most of the cognitive functions studied.
Brain activity also was related to MPOD, but the results were inconsistent.
Only four of the eleven observational studies were based on young people and all studies showed a significant relationship between MPOD and cognitive functions.
This meta-analysis revealed that lutein, zeaxanthin and meso-zeaxanthin supplementation improved MPOD both in AMD patients and healthy subjects with a dose-response relationship.
Ma L et al. · Nutrients (2016)
Spürbar Nutzen
← SchlechterKein EffektBesser →
Xanthophyll carotenoids supplementation was associated with significant increase in MPOD in AMD patients (WMD, 0.07; 95% CI, 0.03 to 0.11) and healthy subjects (WMD, 0.09; 95% CI, 0.05 to 0.14).
Additionally, the changes in MPOD were related with baseline MPOD levels (rAMD = -0.43, p = 0.06; rhealthy subjects = -0.71, p < 0.001) and blood xanthophyll carotenoids concentration (rAMD = 0.40, p = 0.07; rhealthy subjects = 0.33, p = 0.05).
Stratified analysis showed a greater increase in MPOD among trials supplemented and combined with meso-zeaxanthin.
The MP carotenoids filter high-intensity, short-wavelength visible light and are powerful antioxidants in a region vulnerable to light-induced oxidative stress.
Arunkumar R et al. · Biochimica et biophysica acta. Molecular and cell biology of lipids (2020)
The MP carotenoids filter high-intensity, short-wavelength visible light and are powerful antioxidants in a region vulnerable to light-induced oxidative stress.
This review focuses on MP chemistry, absorption, metabolism, transport, and distribution with special emphasis on animal models used for MP study.
This article is part of a Special Issue entitled Carotenoids recent advances in cell and molecular biology edited by Johannes von Lintig and Loredana Quadro.
In this review, we discuss how the differences in the specific properties of lutein and zeaxanthin could help explain the preferential accumulation of zeaxanthin in the most vulnerable region of the macula.
Widomska J et al. · Nutrients (2020)
Zeaxanthin concentrations are 2.5-fold higher than lutein in the cone-dense central fovea.
This is an ~20-fold increase in the molar ratio relative to eccentric retinal regions with biochemically detectable macular xanthophylls.
The distribution of diet-based macular xanthophylls and the lutein metabolite meso-zeaxanthin varies considerably by retinal eccentricity.
The question of an optimal dietary antioxidant supply is evaluated in the context of the dual roles of both oxidants and antioxidants, in all vital functions of living organisms, and the profound impact of individual and environmental context.
Demmig-Adams B et al. · Molecules (Basel, Switzerland) (2020)
This review compares and contrasts the role of carotenoids across the taxa of life-with a focus on the xanthophyll zeaxanthin (and its structural isomer lutein) in plants and humans.
Xanthophylls' multiple protective roles are summarized, with attention to the similarities and differences in the roles of zeaxanthin and lutein in plants versus animals, as well as the role of meso-zeaxanthin in humans.
Detail is provided on the unique control of zeaxanthin function in photosynthesis, that results in its limited availability in leafy vegetables and the human diet.
Next, we turn to clinical evidence supporting functional benefits of these carotenoids in normal eyes and for their potential protective actions against ocular disease from infancy to old age.
Bernstein PS et al. · Progress in retinal and eye research (2016)
Next, we turn to clinical evidence supporting functional benefits of these carotenoids in normal eyes and for their potential protective actions against ocular disease from infancy to old age.
15Lutein and zeaxanthin statusSystematische ÜbersichtCited 126×2016
Accumulating evidence about variable interindividual response to dietary intake of these carotenoids, based on genetic or metabolic influences, suggests that there may be subgroups that benefit from higher levels of intake and/or alternate strategies to improve lutein and zeaxanthin status.
Mares J · Annual review of nutrition (2016)
Additionally, egg yolks and human milk appear to be bioavailable sources.
The prevalence of lutein, zeaxanthin, and meso-zeaxanthin in supplements is increasing.
Setting optimal and safe ranges of intake requires additional research, particularly in pregnant and lactating women.
This 24-month RCT provides direct clinical evidence for meso-zeaxanthin combined carotenoid supplementation improving both macular pigment and visual function in intermediate AMD patients.
Nolan JM et al. · Nutrients (2024)
Significant increases in macular pigment optical density were observed in the supplemented group versus placebo at 24 months
Visual function measures including contrast sensitivity and glare disability improved in the supplemented group
Supplement was well tolerated with no serious adverse events attributed to treatment
17Macular pigment optical densityRCTn=105 · medium study2024
This RCT provides direct evidence for the efficacy of meso-zeaxanthin-containing supplements on macular pigment and vision in healthy adults, extending the evidence base beyond AMD populations.
Nolan JM et al. · Nutrients (2024)
Macular pigment optical density increased significantly with meso-zeaxanthin, lutein, and zeaxanthin supplementation vs. placebo
Visual performance measures including contrast sensitivity showed meaningful improvement in the supplemented group
The supplement combination was well tolerated with no serious adverse events reported
Our data show that L, Z, & MZ supplementation results in decreased serum IL-1β, TNF-α, and OxLDL.
Stringham NT et al. · Nutrition, metabolism, and cardiovascular diseases : NMCD (2024)
Our data show that L, Z, & MZ supplementation results in decreased serum IL-1β, TNF-α, and OxLDL.
This suggests that these carotenoids are acting systemically to attenuate oxidative lipid products and inflammation, thus reducing their contribution to atherosclerotic plaque formation.
Antioxidant supplementation in patients with nonadvanced age-related macular degeneration results in significant increases in macular pigment and improvements in CS and other measures of visual function. (Clinical trial, http://www.isrctn.com/ISRCTN13894787).
Akuffo KO et al. · Investigative ophthalmology & visual science (2017)
There was a statistically significant improvement in the primary outcome measure (letter CS at 6 cycles per degree [6 cpd]) over time (P = 0.013), and this observed improvement was statistically comparable between interventions (P = 0.881).
Statistically significant increases in macular pigment at all eccentricities were observed over time (P < 0.0005, for all), and the degree of augmentation was statistically comparable between interventions (P > 0.05).
Antioxidant supplementation in patients with nonadvanced age-related macular degeneration results in significant increases in macular pigment and improvements in CS and other measures of visual function. (Clinical trial, http://www.isrctn.com/ISRCTN13894787).